

NOVAVAX INC  
Form 8-K  
October 29, 2004

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT UNDER SECTION 13 or 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): October 28, 2004

**NOVAVAX, INC.**

(Exact name of registrant as specified in its charter)

<b><u>Delaware</u></b> (State or other jurisdiction of incorporation or organization)	<b><u>0-26770</u></b> (Commission File No.)	<b><u>22-2816046</u></b> (I.R.S. Employer Identification No.)
---	---	---

<b><u>508 Lapp Road, Malvern, Pennsylvania</u></b> (Address of principal executive offices)	<b><u>19355</u></b> (Zip code)
---	-----------------------------------

**(484) 913-1200**  
Registrant's telephone number, including area code

**8320 Guilford Road, Columbia, Maryland, 21076**  
(Former name or former address, if changed since last report)

---

**NOVAVAX, INC.**  
**ITEMS TO BE INCLUDED IN THIS REPORT**

**ITEM 8 OTHER EVENTS.**

On October 28, 2004, the Company announced the appointment of Susan B. Bayh as a Director to the Novavax, Inc. Board of Directors.

A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by this reference.

**ITEM 9.01 EXHIBITS.**

99.1 Press Release dated October 28, 2004.

**99.2 SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 29, 2004

NOVAVAX, INC.  
By: /s/ Dennis W. Genge  

---

Dennis W. Genge, Vice  
President and  
Chief Financial  
Officer/Treasurer